The Latest Breaking News from MRK

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

The stock indices are down, heading for a second straight losing week on investor concerns about geopolitical tensions and the Fed’s actions. And the market is expected to remain volatile in the near term. Hence, we think high-quality stocks Merck & Co. (MRK), Archer-Daniels-Midland (ADM), Baxter (BAX), McKesson (MCK), and…

Merck & Co Inc's (NYSE: MRK) Q4 sales re

  Merck & Co (NYSE:MRK) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Merck & Co (NYSE:MRK) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will likely report an Earnings Per Share (EPS) of $1.53.

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was 

The market remains turbulent amid worries related to rising inflation, looming interest rate hikes, and geopolitical tensions. However, the Dow Jones Industrial Average is down the least out of the three major indices. Investing in hot Dow stock Merck (MRK), Amgen (AMGN), and Walgreens (WBA) could help safeguard your portfolio…

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,